These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30470647)

  • 41. Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model.
    Dovey Z; Pfail J; Martini A; Steineck G; Dey L; Renström L; Hosseini A; Sfakianos JP; Wiklund P
    Urol Oncol; 2022 Mar; 40(3):106.e1-106.e10. PubMed ID: 34840075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
    Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
    Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
    Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
    World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation.
    Seo KW; Kim BH; Park CH; Kim CI; Chang HS
    Korean J Urol; 2010 Mar; 51(3):165-70. PubMed ID: 20414391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
    Fernandez-Gomez J; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Hernandez R; Madero R; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Isorna S; Rabadan M; Astobieta A; Montesinos M; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2008 May; 53(5):992-1001. PubMed ID: 17950987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.
    Luitel BR; Chalise PR; Nathani S; Gupta DK; Subedi P; Chapagain S; Sharma UK; Gyawali PR; Shrestha GK; Joshi BR
    Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):352-356. PubMed ID: 29371493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J;
    Eur Urol; 2008 Aug; 54(2):303-14. PubMed ID: 18468779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
    van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
    Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Alfred Witjes J; Lebret T; Compérat EM; Cowan NC; De Santis M; Bruins HM; Hernández V; Espinós EL; Dunn J; Rouanne M; Neuzillet Y; Veskimäe E; van der Heijden AG; Gakis G; Ribal MJ
    Eur Urol; 2017 Mar; 71(3):462-475. PubMed ID: 27375033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer.
    Holz S; Albisinni S; Gilsoul J; Pirson M; Duthie V; Quackels T; Vanden Bossche M; Roumeguère T
    Res Rep Urol; 2017; 9():195-202. PubMed ID: 29034222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Fujii Y
    Int J Urol; 2018 Mar; 25(3):212-218. PubMed ID: 29247553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.
    Plasek J; Weissert J; Downs T; Richards K; Ravvaz K
    JMIR Cancer; 2021 Jun; 7(2):e25800. PubMed ID: 34156341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
    Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
    Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
    Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
    van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
    Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
    [No Abstract]   [Full Text] [Related]  

  • 59. NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?
    Lammers RJ; Sylvester RJ; Lee CT; Witjes JA
    Urol Clin North Am; 2013 May; 40(2):155-64. PubMed ID: 23540774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.